...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Back to the draw­ing board for triple-neg­a­tive breast can­cer tar­gets, re­searchers pro­pose new com­bo ap­proach.

Had a conversation with mgmt a couple of months ago 're Rv x and asked about Zenith was told the Breast trial after a Late start was showing great results and that the Prostate trial was to be presented at end of April...that conference is cal  I had PM to a poster at that time  as most were only interested in Rvx

Share
New Message
Please login to post a reply